While the development of targeted treatments for specific genetic mutations, such as the silencing ASO Tofersen in patients carrying certain pathogenic SOD1 variants, addresses only a small subset of the ALS population, these individualized treatment approaches show promising initial results. Here, SOD1 is linked to amyotrophic lateral sclerosis.